An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Semaglutide presents a promising, multi-targeted therapeutic option for addressing the hepatic and systemic consequences of MASH, though final conclusions on long-term clinical outcomes await the ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

Semaglutide shows promise in MASH treatment, achieving significant MASH resolution and fibrosis improvement in the ESSENCE trial. Tolerability issues and insurance coverage challenges lead to 20% ...

All participants also received standard care for MASH. Participants got two liver biopsies to help evaluate the effects of semaglutide. About 56% of participants had type 2 diabetes, and about 73% ...